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57 Anti-IgE therapy for cystic ﬁbrosis patients with difﬁculties in
treating allergic bronchopulmonary aspergillosis
C. Geidel, D. Schu¨ler, K. Weber, P. Bittner-Dersch, H. Lindemann. CF-Center,
Center of Pediatrics and Youth Medicine, University hospital Giessen and Marburg
GmbH, Giessen, Germany
25% of CF-patients have allergic bronchopulmonary aspergillosis (ABPA) – if
patients with early manifestations and without changes in chest x-ray are included.
ABPA is a combined IgE- and IgG-induced allergic inﬂammation. The conventional
therapy is based on exposition prophylaxis, anti-inﬂammatory therapy and if
necessary antimycotics. The aim was if an anti-IgE therapy can affected the disease
process of IgE-related ABPA positively.
A 22y CF patient (chronic Pseudomonas colonisation, 72% vital capacity (VC),
65% forced expiratory volume (FEV1)), constantly Prednisolone (10mg/d) and
Itroconazole, Methylprednisolone-pulse-therapy every 6 weeks, had 4 ABPA exac-
erbations/ year, which needed to be treated in hospital.
A 16y CF patient (chronic Pseudomonas and Burkholderia colonisation, 80% VC,
65% FEV1), constantly Prednisolone (10mg/d), Itroconazole and Methotrexat
(11mg/m2/week), Methylprednisolone-pulse-therapy every 6 weeks, had 3 ABPA
exacerbations/ year, which needed to be treated with high dosed Prednisolone.
The ﬁrst Patient was treated subcutaneous with Omalizumab during 1 year
(2× 300mg/month), the second over 8 months with 1×300mg/month. Both tol-
erated the therapy without complaints. Side effects were not reported. Both patients
could terminate the Methylprednisolone-pulse-therapy. Two episodes of the ABPA
(ﬁrst patient) could be treated ambulant.
Results: The anti-IgE therapy with Omalizumab (Xolair®) can represent an effec-
tive and side effect-poor therapy option if there are difﬁculties in treating ABPA
with conventional therapy. A controlled study for the security and effectiveness of
the therapy with CF patients with ABPA is in planning.
